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ABSTRACT Human exposure to chemical carcinogens is an important etiological factor in cancer diseases. In this 
article, we will discuss a new approach to the development of anticarcinogenic vaccines. The main task in our 
research was to select a benzo[a]pyrene immunomimetic peptide considered as a hapten-specific component. For 
this purpose, we synthesized carcinogen-protein conjugates and prepared mono- and polyclonal antibodies to 
benzo[a]pyrene. Phage display technology was used to select the benzo[a]pyrene immunomimetic peptide, fol-
lowed by an evaluation of the immunological properties of the obtained peptide. The obtained benzo[a]pyrene 
immunomimetic peptide could only simulate chemical carcinogens in the frame of the pIII protein. As a result, 
we prepared a recombinant protein composed of the benzo[a]pyrene immunomimetic peptide and pIII-encoding 
sequences. Using ELISA, we demonstrated that the recombinant protein specifically interacts with the anti-
benzo[a]pyrene monoclonal antibody (mAB B2). Using molecular modeling, we predicted the 3-D structure of 
the mAB B2 active center and analyzed the characteristics of its interaction with different polycyclic aromatic 
hydrocarbons, as well as with the benzo[a]pyrene immunomimetic peptide. Thus, a comprehensive analysis of 
the results of the obtainment of hapten-specific components of anticarcinogenic vaccines allowed us to outline 
a strategy for future development in this direction.
KEY WORDS benzo[a]pyrene, anticarcinogenic vaccine, immunomimetic peptide, phage display, molecular mod-
eling
ABBREVIATIONS CBD – cellulose-binding domain; OD – optical density; BP – benzo[a]pyrene; BSA – bovine 
serum albumin; AB – antibody; mAB – monoclonal antibody; ELISA – enzyme-linked immunosorbent assay; 
PAH – polycyclic aromatic hydrocarbon
INTRODUCTION
The UN Health Agency has reported that more than 
8 million people die from cancer every year. This rein-
forces the need to develop a novel therapeutic strategy 
based on antitumor vaccines. Unfortunately, such vac-
cines commonly target the existing disease rather than 
its cause.
Data from the World Health Organization (WHO) in-
dicate that 90% of cancer cases are a result of the action 
of environmental carcinogenic agents. The bulk (70–
80%) of such agents is made up of chemicals, including 
widely circulating polycyclic aromatic hydrocarbons 
(PAHs). It is an easy guess to assume that the identifi-
cation of carcinogenic substances and their elimination 
from the sphere of human activity could serve as effec-
tive cancer prophylactic. However, such an approach is 
virtually impossible to pursue because of many factors. 
Therefore, the creation of antitumor defense by anti-
carcinogenic vaccines buttressing the immunological 
barrier in animals (including humans) against carcino-
genic chemicals, seems necessary.
Chemical carcinogens are low-molecular substanc-
es that cannot, in themselves, induce an immune re-
sponse. In 1937, Creech and Franks first synthesized 
conjugates of carcinogens with high-molecular carri-
ers - blood serum proteins. They found that immuni-
zation of these conjugates leads to synthesis of specific 
anticarcinogenic antibodies (ABs). At the same time, 
some inhibition of carcinogen-induced tumor progres-
sion was noted following pre-immunization, and the 
idea that the approach could be applied to prevent 
tumor development in humans was first put forward 
[1].
In 1981, Moolten and associates took the next step 
in the development of anticarcinogenic vaccines. They 
prepared protein conjugates with a structural analog 
of carcinogen, which in itself cannot induce a tumor. 
The pre-immunization of animals with this conjugate 
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essentially decreased the probability of tumorigenesis 
caused by an actual carcinogen [2].
A novel approach was used by Chagnaud and associ-
ates. In 1992, they reported the preparation of an anti-
idiotypic monoclonal antibody (mAB) against benzo[a]
pyrene (BP). The second anti-idiotypic mAB carries the   
internal image of a carcinogen and can induce the syn-
thesis of the first ABs against the carcinogen without 
the use of carcinogen-protein conjugates. The inhibi-
tory effect of the second mABs on the development of 
chemically induced tumors was described in 1993 [3].
In the mid-1980s and afterward, Silbart and associ-
ates focused their efforts on the induction of specific 
secretory ABs in the gastrointestinal and respiratory 
mucosa by combining carcinogen-protein conjugates 
with various adjuvants to create a barrier preventing 
carcinogen  transport between the environment and 
the body. In a review published in 1997, Silbart directly 
raised the issue of the future use of anticarcinogenic 
vaccines in humans [4].
Since conjugates of carcinogens or their analogs with 
carrier proteins can lead to iatrogenic induction of tu-
mors, and the introduction of anti-idiotypic ABs – to 
allergic and autoimmune diseases, the proposed ap-
proaches are inapplicable in the development of anti-
carcinogenic vaccines for animals, including humans.
We  offer a fundamentally novel approach in anti-
carcinogenic vaccine development implying the use of 
a peptide as a hapten-specific component that can in-
duce specific anticarcinogenic ABs. Since BP is one of 
the most active and widely distributed PAHs and an 
absolute carcinogen for humans, we set out to prepare 
a peptide immunomimetic of BP.
MATERIALS AND METHODS
Synthesis of conjugates
PAH-protein conjugates of BP, benz[a]anthracene, 
anthracene, chrysene, and pyrene (Aldrich, Germa-
ny) were synthesized by means of covalent binding of 
haptene aldehyde groups with the amino groups of the 
carrier protein (bovine serum albumin [BSA] or hex-
okinase) [5].
Peptide-cBSA conjugates: 2 mg of the synthetic pep-
tide and 10 mg of 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide hydrochloride (EDC) were added to 
700 µL of solution containing 2 mg of cationized BSA 
(cBSA) [6], incubated for 2 hours, and dialyzed six times 
against 1 L of H2O.
Immunization of laboratory animals
Preparation of hybridomas producing mABs specific to 
BP: hybridomas were prepared by the fusion of murine 
Sp2/0 myeloma cells and female Balb/c mouse spleno-
cytes following immunization with the BP-BSA conju-
gate [7], as described by Kohler G. and Milstein C. [8].
Preparation of polyclonal ABs against BP: rabbits 
were immunized with 2 mg of the BP-BSA conjugate 
by weekly intramuscular injections for three weeks. 
The first injection was performed with the mixture of 
the antigen with a complete Freund’s adjuvant (CFA) 
(Sigma, USA); the second – with the mixture of the 
antigen with a incomplete Freund’s adjuvant; and the 
third – with the antigen in PBS. Then, supporting in-
jections were introduced once in two weeks. Blood was 
taken two months after the beginning of immunization 
– every other week.
Immunization of animals with a chimeric protein 
containing a BP immunomimetic peptide: Balb/c mice 
were immunized by intraperitoneal injections of a chi-
meric protein four times once every two weeks. For the 
first injection, the antigen was mixed with CFA. Other 
injections were performed using the antigen mixture 
with an incomplete Freund’s adjuvant. The amount 
of the antigen was 100–150 mg. The blood serum was 
tested for specific ABs against PAH, beginning from 
the first injection.
Purifucation of anti-BP ABs was carried out by af-
finity chromatography on columns filled with PAH-
hexokinase-Sepharose 4B [9]. The replacement of the 
carrier protein enabled to avoid a preliminary purifica-
tion of the antiserum from admixing ABs against the 
protein carrier used for immunization (anti-BSA ABs).
ELISA
Identification of specific anti-PAH-BSA ABs by ELISA: 
PAH-BSA conjugate (5 µg/mL, 100 µL in each well) 
was sorbed into wells of a polystyrene 96-well plates 
(Medpolymer, Russia) for 12 hours at 4°C. Nonspecif-
ic binding sites were blocked with 0.5% BSA in PBS, 
pH 7.2–7.4, containing 8 g of NaCl, 0.2 g of KCl, 2.68 g 
of Na2HPO4 × 7H2O, 0.24 g of KH2PO in 1 L of water,   
then100 µL of blood serum samples serial dilutions in 
PBS containing 0.05% Tween-20 (PBST) and 0.5% BSA 
were added into the wells. Unbound material was re-
moved by washing with PBST and PBS, and bound 
ABs were detected by treatment with an anti-mouse 
IgG horseradish peroxidase (Biosan, Russia) conjugate, 
followed by staining with TMB (Fluka, Switzerland). 
The optical density was determined on a microplate 
reader (FFM, Russia) at 450 nm.
To detect a specific binding of the chimeric protein 
with anti-BP ABs, The mono- or polyclonal AB to BP 
(5 µg/mL) was sorbed into wells of a polystyrene 96-
well plate. Following blocking, serial dilutions of the 
chimeric protein in PBST containing 0.5% BSA (100 µL 
per a well) were added and incubated. The plates were 
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against a cellulose-binding domain (CBD) was added 
into each well followed by incubation, while the bound 
recombinant proteins were detected with an anti-rab-
bit IgG horseradish peroxidase conjugate as described 
above. The experiment was triplicated for estimation 
of reproducibility.
Competitive ELISA: conjugate BP-BSA (5 µg/mL) 
was sorbed into wells of a polystyrene 96-well plate. 
Following blocking, a mixture of mAB B2 of equal con-
centration with varied amounts of a competitor (PAH 
or synthetic peptide) was added into the wells. The 
mAB B2-competitor mixtures (total volume 100 µL, 
each) were preincubated for 30 min at 37°C and shak-
en gently. All tested samples were diluted with PBST 
containing BSA. The plates were incubated for 1 hour 
at 37°C and shaken gently. Then, following thorough 
washing with PBST, the bound mABs were detected 
with an anti-mouse IgG horseradish peroxidase con-
jugate as described above. The experiment was tripli-
cated for estimation of reproducibility.
Affinity selection of phage display peptide library 
was carried out according to the recommended protocol 
to the Ph.D-12TM kit (New England BioLabs), with ad-
ditional modifications [10].
Chemical synthesis of peptides by the method of ac-
tivated esters in solution was performed in the Labora-
tory of Organic Synthesis, Institute of Chemical Biology 
and Fundamental Medicine, SB, RAS.
Molecular modeling.
Optimum patterns for the AB structure modeling by 
homology were matched using the BLAST server. 
Modeling was performed using the Modeller9v1 soft-
ware. Molecular docking was performed using Auto-
Dock version 4.0. Construction of the model for a pep-
tide comprising the pIII protein was performed using 
the Rosetta program for de novo modeling [11].
RESULTS AND DISCUSSION
Synthesis of PAH-protein conjugates for preparation 
and analysis of antibodies
A major shortcoming of known methods of PAH-pro-
tein conjugate synthesis including the preparation of 
BP conjugates with proteins is the formation of a poly-
mer, which considerably decreases the yield of the sol-
uble fraction and, as a result, makes this conjugate un-
suitable for immunoassay. So, the main task in this set 
of studies was to prepare well-soluble hapten-protein 
conjugates that contain a minimum of the polymeric 
admixture and are stable without the need for specific 
stabilizers.
We applied a method of covalent hapten-protein 
binding via the formation of an azomethine bond be-
tween an aldehyde group of hapten and amine groups 
of protein [5]. The use of BP aldehyde for the synthe-
sis of conjugates with proteins enabled good results: 
animal blood sera with high titers of anti-BP ABs were 
obtained. Immunization with a hapten bound with one 
carrier protein (for example BSA) followed by the de-
tection of ABs against this hapten based on another 
carrier protein (hexokinase) was found to be highly 
effective in both the analysis of anti-BP ABs in direct 
and competitive ELISA and the one-step preparation 
of affinity-purified ABs against PAH [9].
Preparation and immunochemical characterization of 
a monoclonal antibody against benzo[a]pyrene
There are several anti-BP mABs available in the world 
currently (USA, Czech Republic, Japan). They were 
raised mainly for the development of ELIZA-based 
test-systems to detect PAH pollutants in the environ-
ment, as well as their metabolites and DNA-adducts 
in the biological fluids of animals, including humans 
[12–14]. The main shortcoming of these mABs – in the 
case of hapten-specific vaccine component preparation 
– is the insufficient specificity of their binding with BP, 
compared with noncarcinogenic PAH. Besides, the ca-
pability of the abovementioned mABs to bind with hy-
drophobic endobiotics (steroid hormones) and aromatic 
aminoacids hasn’t been  studied yet . So, the key stage 
in our work was the preparation of a highly specific an-
ti-BP mAB and the analysis of its cross-reactions with 
other PAHs, steroid hormones, and aromatic aminoac-
ids.
Among the obtained murine hybridoma clones, the 
clone B2 was chosen producing IgG mAB, which had 
no affinity to the anthracene-BSA conjugate and had 
low affinity to chrysene-BSA and pyrene-BSA con-
jugates. The mAB B2 most effectively binds BP and 
benz[a]anthracene, a putative human carcinogen [7].
We checked for the possibility of cross-reaction of 
the mAB B2 with aminoacids, such as tryptophan and 
phenylalanine, based on the belief that the presence 
of an aromatic ring is one of the requirements of the 
interaction of anti-PAH AB with other substances. It 
is known that one aryl hydrocarbon receptor is impli-
cated in signal transduction from PAH and endogenous 
substrates (in particular, estrogens); so, we also studied 
the cross-reaction of the mAB B2 with these substanc-
es and found no binding. This excludes the probability 
of preparing an anticarcinogenic vaccine with a side 
effect such as inducing autoimmune reactions against 
endogenous ligands.
Preparation and characterization of a benzo[a]pyrene 
immunomimetic peptide
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for a BP immunomimetic peptide. The procedure of af-
finity selection included incubation of the Ph.D-12TM 
initial library with mono- and polyclonal ABs to BP and 
washing from AB-unbound and elution of bound bacte-
riophages. The preliminary procedure of bacteriophage 
exhaustion with intact murine or rabbit IgG was sub-
stituted with cross-mapping of ABs in the third round 
of selection; i.e., the first two rounds were carried out 
on single species ABs, for instance mAb B2, and poly-
clonal ABs against BP were mapped with the obtained 
bacteriophage population in the third round, and vice 
versa. The proposed approach should favor the selec-
tion of high-affinity bacteriophage clones.
Five resulting bacteriophage clones were produced 
that specifically interact with mAB B2. Four clones re-
sulted from cross-selection, when the two first rounds 
were carried out on mAB B2, and the last round – on 
polyclonal ABs to BP. One clone was produced when all 
selection rounds were carried out on mAB B2. DNA se-
quencing of these clones, followed by translation, dem-
onstrated that all five clones had an identical aminoacid 
sequence of the recombinant peptide: LeuHisLeuPro-
HisHisAspGlyValGlyTrpGly [10, 15].
The BP immunomimetic peptide (named PiP) was 
synthesized for further study of its immunochemical 
properties. Since two halves of the PiP, LeuHisLeuPro-
HisHis (LH-peptide) and AspGlyValGlyTrpGly (DG-
peptide), were synthesized first and then linked, we 
also evaluated LH- and DG-peptides for specific inter-
action with mAB B2.
Since the PAH structural mimicry is supposed to de-
pend on the presence of a tryptophan residue within 
the peptide sequence, tryptophan was used as a nega-
tive control.
Synthetic peptides were found to compete with 
the BP-BSA conjugate for the binding with mAB B2. 
However, their binding force is substantially weaker 
than that of BP. Tryptophan (Trp) did not demonstrate 
any significant competition for binding with mAB B2 
(Fig. 1). This fact suggests that Trp can specifically bind 
with ABs against the PAH group of chemical carcino-
gens, only when in context with other amino acid resi-
dues of these peptides.
The nature of LH-peptide binding with mAB B2 re-
mains an enigma. One can speculate that a very complex 
interaction takes places between the PiP peptide and 
mAB B2, which cannot be explained by the fact that Trp 
or other hydrophobic residues structurally mimic BP.
Analysis of blood sera from mice immunized with 
peptide–cBSA conjugates revealed the presence of 
ABs to benz[a]anthracene and anthracene. However, 
their level is an order of magnitude lower than that of 
anti-PAH ABs induced by the immunization of mice 
with BP-BSA [11].
Several reports on the production of the peptide mi-
metic of low-molecular compounds have shown that 
the initial conformation of peptides present on the sur-
face of a bacteriophage carrier can change when the 
peptide is disengaged, or undergo additional modifica-
tion. These alterations are crucial for ABs to recognize 
a peptide [16].
Thus, using the Rosetta software, we constructed a 
model for the peptide portion within the bacteriophage 
M13 pIII protein. The model assumes that the Trp side 
radical is localized on the surface of the protein [11]. It 
is likely that the structure of a peptide immunomimetic 
enabling mimicry of PAH-type carcinogens is possible 
only within the context of the pIII protein. In this con-
text, our efforts therefore focused on the production of 
a recombinant protein composed of the BP immunomi-
metic peptide and bacteriophage pIII protein.
Preparation and characterization of a recombinant 
protein containing the benzo[a]pyrene immunomi-
metic peptide
Several approaches in gene engineering are known to 
enable an increase in the expression level and stability 
of transgenic proteins in a bacterial system, the facilita-
tion of the testing procedure, and to enhance efficiency 
in protein purification. One of these approaches is a fu-
sion technique directed toward the synthesis of chi-
meric proteins. It is based on the linkage of two genes 
(a gene for the antigene component and that encoding 
a carrier protein) in one reading frame, which leads to 
the synthesis of a chimeric protein in the bacterial sys-
tem [17].
Using this technology, we produced and character-
ized the chimeric protein whose antigen component 
comprises amino acid sequences of a BP immunomi-
metic peptide and the pIII protein of bacteriophage 
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Fig. 1. Competitive inhibition of mAb B2 binding with im-
mobilized conjugate BP-BSA by BP, DG, LH, PiP, and Trp.RESEARCH ARTICLES
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M13, on the basis of which the Ph.D-12TM library was 
constructed. A CBD-domain of Anaerocellum ther-
mophilum endoglucanase was used as a carrier. It can 
interact with high affinity with a cellulose sorbent, 
thus enabling the isolation and purification of the re-
combinant protein containing the immunomimetic 
peptide.
Noncompetitive ELISA was used in the study of the 
interaction between mAB B2 and the produced chi-
meric protein containing the antigen component (BP 
immunomimetic peptide within the pIII protein) and 
the carrier protein (CBD). CBD was used as the nega-
tive control. The ability of the chimeric protein contain-
ing the immunomimetic peptide to bind with mAB B2 
sorbed on a plastic was found to be dose-dependent 
(Fig. 2). The chimeric protein did not bind polyclonal 
murine and rabbit ABs to BP.
Balb/c mice were intraperitoneally immunized with 
the chimeric protein to test for the ability of the im-
munomimetic peptide within the bacteriophage pIII 
to induce ABs against PAH. A low level of anti-PAH 
ABs was detected in the blood serum of immunized 
mice. The most prominent binding was detected be-
tween the ABs and anthracene. At the same time, the 
blood serum of mice immunized with the bacteriophage 
recombinant clone containing the BP immunomimetic 
peptide within the pIII protein contains a mAB against 
BP, wherein the titers are comparable with those in 
the positive control – immunization with the BP-BSA 
conjugate [10, 15].
With the aim to find approaches to enhancing chi-
meric protein immunogenicity in relation to BP, we 
studied – using molecular modeling – the spatial 
structure of the mAB B2 active center and the features 
characterizing its interaction with PAHs and the im-
munomimetic peptide.
Peculiarities of the interaction between mAB B2 and 
benzo[a]pyrene immunomimetic peptide
A model for the mAB B2 Fab-fragment was created by 
the method of homology using the determined primary 
structures of heavy and light chains. The average bind-
ing energy between the mAB B2 Fab-fragment and 
several PAHs calculated using molecular docking soft-
ware correlated with the experimental data on cross-
reactivity between mAB B2 and these PAHs, thus con-
firming the validity of the created model [11].
Two pockets for PAH binding possibly exist in the 
active center of mAB B2, as was determined by molec-
ular docking. The best position for BP and other PAH 
binding was determined to be between the third loops 
of the light and heavy chains of mAB B2 (this pocket 
was named P1). Two variants of BP docking in the P1 
pocket were determined: the vertical and the horizon-
tal, the first and the second one, respectively. The sec-
ond pocket between the second loop of the light chain 
and the third loop of the heavy chain was less profound 
and less preferable for PAH binding, judging from the 
higher binding energy predicted by the docking (this 
pocket was conditionally named P2) [11].
A number of molecular docking calculations for the 
mAB B2 Fab-fragment with tripeptides comprising 
PiP have been carried out with the aim of modeling 
the interaction between the LeuHisLeuProHisHisAs-
pGlyValGlyTrpGly peptide and mAB B2. None of the 
tripeptides binds with ABs in the region of the first 
pocket. Several tripeptides (HisLeuPro, LeuProHis, 
ProHisHis, and GlyTrpGly) have bound with Ab in the 
region of the second pocket (Fig. 3). Three tripeptides 
are convergent in the presence of a histidine residue, 
which is not shielded by other amino acid residues. This 
explains the LH-peptide’s ability to compete with the 
BP-BSA conjugate for mAB B2.
At the same time, tryptophan, being within the BP 
immunomimetic peptide, obviously plays the key role 
in the binding of mAB B2, if the latter is exposed to the 
protein’s surface. This immunomimetic peptide struc-
ture is possible within the pIII protein structure.
When the presence of the second binding pocket in 
the active center of mAB B2 is taken into account, one 
can explain the fact that the chimeric protein contain-
ing the immunomimetic peptide actively binds only to 
mAb B2, but not other polyclonal ABs against BP.
It is likely that in the process of recombinant bacte-
riophage selection on mAb B2, the peptides were se-
lected by their binding with the second pocket as the 
most desired one. It is possible that the initial library 
contained no peptide capable of specifically binding 
with the deeper first pocket. The fact that no clones 
capable of specifically binding with the mAB B2 were 
found among the recombinant bacteriophages that re-
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Fig. 2. Binding of chimeric protein containing benzo[a]
pyrene immunomimetic peptide with mAB B2.110 | ACTA NATURAE |  VOL. 2  № 4 (7)  2010
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sulted from the affinity selection on polyclonal ABs, 
as well as the fact that all five clones had an identical 
amino acid sequence, confirms the abovementioned 
hypothesis.
The experimentally revealed weak reverse-mimic-
ry in vivo, i.e. weak immune reaction between AB and 
PAH, when mice were immunized with chimeric pro-
tein can be explained as follows.
As mentioned above, tryptophan has the closest 
structural similarity to BP among all side radicals. Su-
perposition of the tryptophan and BP structures at 
the first position of the P1 pocket demonstrates that 
tryptophan, being within the polypeptide chain, can-
not bind to such a deep cavity, because the length of 
BP exceeds that of the tryptophan side radical. At the 
same time, BP structural mimicry by tryptophan, in 
combination with some other side aminoacid radicals, 
is possible in the second position of the P1 pocket. It 
is likely that some part of AB induced by immuniza-
tion with the immunomimetic peptide has a cavity for 
binding which is similar to the P2 pocket: therefore, 
tryptophan binding to AB does not generally bind to 
BP. Other parts of AB can possess a cavity for the bind-
ing of the P1 pocket’s second position, enabling them to 
bind PAHs, including BP.
CONCLUSION
The use of conjugates of chemical carcinogens (or their 
structural analogs) with macromolecular carriers as 
vaccines is completely unacceptable in the immune 
prophylaxis of malignant tumors in humans because 
of the risk that the vaccine itself can induce a tumor. 
The hybridoma technique for the production of anti-
idiotypic ABs has limitations in the optimization of the 
immunogenic properties of target vaccines. In addition, 
it is complex and expensive.
The proposed approach, i.e. the production of im-
mune peptides that mimic chemical carcinogens using 
phage display technology, is preferable.
The mAB B2 obtained in our experiments possesses 
high specificity to BP, low cross-reactivity with non-
carcinogenic PAHs, and does not react with endobiot-
ics. Moreover, molecular docking showed that the pre-
dicted average energy for dibenzo[a]pyrene binding to 
the mAB B2 Fab-fragment is –8.91 kcal/mol, which is 
higher than the values for BP and other PAHs. We have 
established a direct correlation between the predicted 
binding energy and the experimentally measured PAH 
cross-reactivity. Based on this, one can surmise that the 
usage of mAB B2 in phage display technology could be 
effective in the search for immune peptides that mimic 
not only BP, but other PAHs with higher carcinogenic 
activity as well.
It is important to note that anti-idiotypic mABs are 
produced when animals are immunized with polyclo-
nal ABs to BP [3]. In this context, the right strategy 
going forward will be to use new molecular targets in 
the search for PAH immunomimetic peptides. In our 
opinion, the use of the recombinant Fab-fragment of 
the mAB B2 with its second pocket removed via site-
directed mutagenesis seems to be the most successful 
avenue. The recombinant bacteriophages resulting 
from the selection on such AB must be tested for bind-
ing with polyclonal ABs against BP.
The second method in enhancing the immunogenic-
ity of target vaccines against carcinogenic PAHs would 
be the use of other phage libraries and/or optimization 
of the recombinant peptide structure via point muta-
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Fig. 3. The struc-
ture models of 
BP, GlyTrpGly, 
and ProHisHis 
complexes with 
the active center 
of the mAB B2 
Fab-fragment. BP 
binding in posi-
tions P1P1 (A), 
P1P2 (B), and P2 
(C); GlyTrpGly 
(D) and ProHisHis 
(E) binding in 
position P2.RESEARCH ARTICLES
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tions. This approach could enable the production of a 
peptide inducing a highly specific immune response to 
BP and more carcinogenic PAHs.  
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